Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
15
AKYA Quote, Financials, Valuation and Earnings
Last price:
$2.49
Seasonality move
:
-6.47%
Day range:
$2.34 - $2.60
52-week range:
$1.88 - $6.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.41x
P/B ratio:
9.02x
Volume:
365.6K
Avg. volume:
354.6K
1-year change:
-47.35%
Market cap:
$122.9M
Revenue:
$96.6M
EPS (TTM):
-$1.18
Analysts' Opinion
-
Consensus RatingAkoya Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Akoya Biosciences has an estimated upside of 41.13% from its current price of $2.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.48.
Fair Value
-
According to the consensus of 0 analysts, Akoya Biosciences has 41.13% upside to fair value with a price target of -- per share.
AKYA vs. S&P 500
-
Over the past 5 trading days, Akoya Biosciences has overperformed the S&P 500 by 11.47% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Akoya Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Akoya Biosciences revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Akoya Biosciences reported revenues of $18.8M.
Earnings Growth
-
Akoya Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Akoya Biosciences reported earnings per share of -$0.21.
Enterprise value:
162.9M
EV / Invested capital:
1.82x
Price / LTM sales:
1.41x
EV / EBIT:
--
EV / Revenue:
1.88x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$50.1M
Return On Assets:
-36.87%
Net Income Margin (TTM):
-66.77%
Return On Equity:
-157.22%
Return On Invested Capital:
-52.65%
Operating Margin:
-39.45%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $69.8M | $91.4M | $86.8M | $25.2M | $18.8M | |
| Gross Profit | $41.6M | $51.7M | $50.1M | $15.3M | $11.7M | |
| Operating Income | -$64.9M | -$64.3M | -$44.3M | -$11.3M | -$7.4M | |
| EBITDA | -$59.2M | -$54.4M | -$39.8M | -$8.1M | -$6M | |
| Diluted EPS | -$1.85 | -$1.76 | -$1.18 | -$0.26 | -$0.21 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $145.7M | $111.7M | $116.9M | $76.9M | |
| Total Assets | -- | $195.4M | $176.5M | $177.2M | $130M | |
| Current Liabilities | -- | $17.3M | $31.7M | $35.5M | $28M | |
| Total Liabilities | -- | $58M | $101.4M | $115.3M | $116.3M | |
| Total Equity | -- | $137.4M | $75.1M | $62M | $13.6M | |
| Total Debt | -- | $32.4M | $52.7M | $63.8M | $75.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$49.3M | -$55.3M | -$46.7M | -$13.8M | -$9.3M | |
| Cash From Investing | -$37.6M | $26.1M | -$27.3M | -$832K | $13M | |
| Cash From Financing | $18.6M | $56M | $8.4M | -$141K | -$150K | |
| Free Cash Flow | -$57.2M | -$59.3M | -$48.7M | -$14.6M | -$9.7M | |
AKYA
Sector
Market Cap
$122.9M
$44.6M
Price % of 52-Week High
39.3%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-47.35%
-29.09%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$2.46
200-day SMA
Sell
Level
$2.94
Bollinger Bands (100)
Sell
Level
2.24 - 2.96
Chaikin Money Flow
Sell
Level
-544.8K
20-day SMA
Buy
Level
$2.29
Relative Strength Index (RSI14)
Buy
Level
51.56
ADX Line
Sell
Level
0.79
Williams %R
Neutral
Level
-32.8358
50-day SMA
Sell
Level
$2.64
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Sell
Level
-1.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.5364)
Sell
CA Score
(Annual)
Level (-2.4801)
Buy
Beneish M-Score
(Annual)
Level (-2.2767)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (3.6128)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler® (formerly CODEX) and PhenoImager® (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
Stock Forecast FAQ
In the current month, AKYA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AKYA average analyst price target in the past 3 months is --.
-
Where Will Akoya Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Akoya Biosciences share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Akoya Biosciences?
Analysts are divided on their view about Akoya Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Akoya Biosciences is a Sell and believe this share price will drop from its current level to --.
-
What Is Akoya Biosciences's Price Target?
The price target for Akoya Biosciences over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AKYA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Akoya Biosciences is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AKYA?
You can purchase shares of Akoya Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Akoya Biosciences shares.
-
What Is The Akoya Biosciences Share Price Today?
Akoya Biosciences was last trading at $2.49 per share. This represents the most recent stock quote for Akoya Biosciences. Yesterday, Akoya Biosciences closed at $2.48 per share.
-
How To Buy Akoya Biosciences Stock Online?
In order to purchase Akoya Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
